Restoring 14-3-3/CRAF Interaction in Noonan Syndrome via Molecular Glues
A study published in the Proceedings of the National Academy of Sciences (PNAS) in May 2026 details a novel therapeutic approach for Noonan syndrome, a genetic disorder classified as a RASopathy. The research focuses on CRAF kinase, a critical component of the MAPK signaling pathway. Under normal physiological conditions, CRAF is autoinhibited through phosphorylation at serine 259 (S259), which facilitates binding to the adaptor protein 14-3-3, resulting in an inactive complex. In Noonan syndrome, this regulatory mechanism is disrupted, leading to hyperactive signaling and associated developmental abnormalities. The investigators demonstrate that molecular glues can effectively restore the interaction between 14-3-3 and CRAF. By stabilizing this inhibitory complex, the molecular glues suppress the aberrant MAPK pathway activity characteristic of the disease. This finding represents a significant advancement in targeted therapy for RASopathies, offering a potential strategy to correct specific protein-protein interaction defects rather than broadly inhibiting kinase activity. The work highlights the potential of proteostasis regulators and molecular glue degraders or stabilizers in treating genetic disorders driven by signaling pathway dysregulation, providing a new avenue for drug development in rare diseases.
Wire timeline
Restoring 14-3-3/CRAF Interaction in Noonan Syndrome via Molecular Glues
A study published in the Proceedings of the National Academy of Sciences (PNAS) in May 2026 details a novel therapeutic approach for Noonan syndrome, a genetic disorder classified as a RASopathy. The research focuses on CRAF kinase, a critical component of the MAPK signaling pathway. Under normal physiological conditions, CRAF is autoinhibited through phosphorylation at serine 259 (S259), which facilitates binding to the adaptor protein 14-3-3, resulting in an inactive complex. In Noonan syndrome, this regulatory mechanism is disrupted, leading to hyperactive signaling and associated developmental abnormalities. The investigators demonstrate that molecular glues can effectively restore the interaction between 14-3-3 and CRAF. By stabilizing this inhibitory complex, the molecular glues suppress the aberrant MAPK pathway activity characteristic of the disease. This finding represents a significant advancement in targeted therapy for RASopathies, offering a potential strategy to correct specific protein-protein interaction defects rather than broadly inhibiting kinase activity. The work highlights the potential of proteostasis regulators and molecular glue degraders or stabilizers in treating genetic disorders driven by signaling pathway dysregulation, providing a new avenue for drug development in rare diseases.
Proceedings of the National Academy of Sciences: Proceedings of the National Academy of Sciences: Table of Contents